Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 6,989% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 0.9% — below-average profitability
- Revenue growing at 27% annually
Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $8.9 billion . Key value metrics: P/E ratio 3,513.9, P/B ratio 32.18, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Pharming Group N.V. - ADS, each representing 10 ordinary shares — Fundamental Analysis Summary
Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR) is currently trading 6,989% above its Graham Number of $0.18, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 3,513.9x.
On financial health, PHAR shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 0.9% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for PHAR is 34/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PHAR reports a high gross margin of 87.9% (sector average: 39.4%) and a modest operating margin of 6.9%.
PHAR shows revenue growing at 27% year-over-year, with earnings growing at 121%.